Fig. 4.

The therapeutic effect of rIL-27 in a clinically relevant mouse model of ICH. ICH in mice was induced using autologous blood injection. The rIL-27 treatment was initiated at 30 min after ICH by i.v. injection and then daily by s.c. injection for 6 days, each treatment at 50 ng/kg. The outcome include: a the individual behavioral/NDS of footfault, circling, wire, postural flexing, and forward placing test, and grand NDS, a composite NDS score on day 1–14 after ICH (n = 8) The data were expressed as mean ± SEM and *p < 0.05 was established using one-way ANOVA followed by Newman–Keuls post-test. b Brain edema (water content) on day 3 (n = 5); e hemoglobin (Hb) and f iron content in ICH-affected brain (index of hematoma removal) on day 7 (n = 5). c The grand NDS on day 3 after ICH in mice treated with rIL-27 and with Ly-6G or rat isotype IgG, control. Twenty-four of C57/BJ6 mice were treated with rIL-27 (Biolegend, 577404, a heterodimer of mouse recombinant IL-27 EBI3 and p28 linked by a GGGSGGGSGGGTGGGS linker), 50 ng/kg by i.v. at 30 min and then daily s.c., on day 1–3 after ICH. To deplete neutrophils, 12 mice were injected with Ly-6G, a neutrophil neutralizing antibody (BioXCell, 1A8, BE0075) at 500 μg/mouse at 2, 24, and 72 h after ICH (i.p.). And 12 mice were injected with rat isotype IgG (IgG2a, BioXCell, 2A3, BE0089). The NDS were quantified with three behavioral tests (postural flexing, circling, and footfault) 3 days after ICH. d The percent change of body weight on day 3 (compared with the body weight on day 0, right prior to ICH). In b–f, all data were expressed as mean ± SEM. *p ≤ 0.05, compared with the corresponding vehicle control, established using paired t-test